98%
921
2 minutes
20
Mucositis, or damage/injury to mucous membranes of the alimentary, respiratory, or genitourinary tract, is the major side effect associated with anticancer radiotherapies. Because there is no effective treatment for mucositis at present, this is a particular issue as it limits the dose of therapy in cancer patients and significantly affects their quality of life. Gastrointestinal mucositis (GIM) occurs in patients receiving radiotherapies to treat cancers of the stomach, abdomen, and pelvis. It involves inflammation and ulceration of the gastrointestinal (GI) tract causing diarrhea, nausea and vomiting, abdominal pain, and bloating. However, there is currently no effective treatment for this debilitating condition. In this study, we investigated the potential of a type of traditional Chinese medicine (TCM), compound Kushen injection (CKI), as a treatment for GIM. It has previously been shown that major groups of chemical compounds found in CKI have anti-inflammatory effects and are capable of inhibiting the expression of pro-inflammatory cytokines. Intraperitoneal administration of CKI to Sprague Dawley (SD) rats that concurrently received abdominal irradiation over five fractions resulted in reduced severity of GIM symptoms compared to rats administered a vehicle control. Histological examination of the intestinal tissues revealed significantly less damaged villus epithelium in CKI-administered rats that had reduced numbers of apoptotic cells in the crypts. Furthermore, it was also found that CKI treatment led to decreased levels of inflammatory factors including lower levels of interleukin (IL)-1β and IL-6 as well as myeloperoxidase (MPO)-producing cells in the intestinal mucosa. Together, our data indicate a novel effect of CKI to reduce the symptoms of radiation-induced GIM by inhibiting inflammation in the mucosa and apoptosis of epithelial cells.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403047 | PMC |
http://dx.doi.org/10.3389/fonc.2022.929735 | DOI Listing |
Curr Drug Res Rev
August 2025
School of Life Sciences, Beijing University of Chinese Medicine, Beijing, 102488, China.
Background: Hepatocellular carcinoma (HCC), commonly referred to as primary liver cancer, is a malignant neoplasm that originates within the liver. Conventional treatment modalities frequently result in less than satisfactory outcomes, primarily attributed to the intricate physiological and pathological contexts. Compound Kushen Injection (CKI), formulated from the botanicals Sophora flavescens and Atractylodes macrocephala, is employed as a supplementary therapy in the treatment of advanced-stage malignant tumors, including HCC.
View Article and Find Full Text PDFPhytomedicine
August 2025
Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, PR China; Research Center for Lifespan Health, Wuhan University, Wuhan, Hubei, 430071, PR China. Electronic address:
Background: Multiple myeloma (MM) is a plasma cell malignancy that remains incurable due to inevitable relapse and poor treatment tolerance. Compound Kushen Injection (CKI), a traditional Chinese medicinal formulation, has been reported to exert anti-tumor effects in various cancers, but its efficacy and mechanisms in MM remain unclear.
Purpose: This study aimed to elucidate the anti-MM mechanisms of CKI, focusing on its induction of DNA damage response (DDR) and endoplasmic reticulum (ER) stress, and to assess synergy with proteasome inhibitors (PIs).
J Ethnopharmacol
August 2025
Beijing Zhendong Guangming Pharmaceutical Research Institute, Beijing, 100085, China. Electronic address:
Ethnopharmacological Relevance: In traditional Chinese medicine (TCM) theory, Compound Kushen Injection (CKI) possesses multiple therapeutic effects, including heat-clearing, detoxification, blood-cooling, dampness-resolving, and pain relief. CKI has been used clinically for 30 years as an adjunctive drug alongside chemotherapy and radiotherapy for cancer treatment. However, the effects of CKI on cancer-induced bone pain (CIBP) and potential mechanisms remain poorly understood.
View Article and Find Full Text PDFWorld J Gastrointest Oncol
July 2025
The First Department of Oncology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031, Anhui Province, China.
Background: Advanced hepatocellular carcinoma (HCC) with ascites (AS) lacks reliable biomarkers for predicting treatment outcomes. The combined prognostic value of the systemic immune-inflammation index (SII) and prognostic nutritional index (PNI) remains underexplored for novel therapies.
Aim: To evaluate the clinical efficacy of combining intraperitoneal compound Kushen injection (CKI) with immunotherapy in patients with advanced HCC using a scoring system that combines SII and PNI.
Phytother Res
August 2025
Institute of Traditional Chinese Medicine and Stem Cell Research, College of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Atopic dermatitis (AD) is a chronic inflammatory skin disorder with limited effective treatment. Sophora flavescens Aiton (Kushen) exhibits anti-inflammatory properties, but its key active components and mechanisms against AD remain unclear. This study aimed to identify its therapeutic compounds and the underlying molecular mechanisms.
View Article and Find Full Text PDF